Effect of St. John's wort supplementation on the pharmacokinetics of bupropion in healthy male Chinese volunteers - PubMed

Abstract

The objective of this study was to investigate the effects of continuous St. John's wort administration on single-dose pharmacokinetics of bupropion, a substrate of cytochrome P450 (CYP) 2B6, in healthy Chinese volunteers. Eighteen unrelated healthy male subjects participated in this study. The single-dose pharmacokinetics of bupropion and hydroxybupropion were determined before (control) and after a long-term period of St. John's wort intake (325 mg, three times a day for 14 days). Plasma concentrations of bupropion and hydroxybupropion were determined before and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 60 and 72 h after dosing. St. John's wort treatment decreased the area under the concentration versus time curve extrapolated to infinity of bupropion in healthy volunteers from 1.4 microg.h ml(-1) (95% confidence interval [CI] = 1.2-1.6 microg.h ml(-1)) after bupropion alone to 1.2 microg.h ml(-1) (95% CI = 1.1-1.3 microg.h ml(-1)) during St. John's wort treatment. St. John's wort treatment increased the oral clearance of bupropion from 108.3 l h(-1) (95% CI = 95.4-123.0 l h(-1)) to 130.0 l h(-1) (95% CI = 118.4-142.7 l h(-1)). No change in the time to peak concentration (t(max)) and the blood elimination half-life (t(1/2)) of bupropion was observed between the control and St. John's wort-treated phases. However, the half-life of hydroxybupropion between two phases had a significant difference by a Student's t test after logarithmic transformation. St. John's wort treatment decreased the half-life of hydroxybupropion from 26.7 h (95% CI = 23.8-29.9 h) to 24.4 h (95% CI = 21.9-27.3 h). St. John's wort decreased, to a statistically significant extent, the plasma concentrations of bupropion, probably mainly by increasing the clearance of bupropion.

Similar articles

• Effect of St John's wort on imatinib mesylate pharmacokinetics.

  Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ. Frye RF, et al. Clin Pharmacol Ther. 2004 Oct;76(4):323-9. doi: 10.1016/j.clpt.2004.06.007. Clin Pharmacol Ther. 2004. PMID: 15470331 Clinical Trial.

• Effects of St. John's wort supplementation on ibuprofen pharmacokinetics.

  Bell EC, Ravis WR, Lloyd KB, Stokes TJ. Bell EC, et al. Ann Pharmacother. 2007 Feb;41(2):229-34. doi: 10.1345/aph.1H602. Epub 2007 Feb 6. Ann Pharmacother. 2007. PMID: 17284505 Clinical Trial.

• Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers.

  Burstein AH, Horton RL, Dunn T, Alfaro RM, Piscitelli SC, Theodore W. Burstein AH, et al. Clin Pharmacol Ther. 2000 Dec;68(6):605-12. doi: 10.1067/mcp.2000.111530. Clin Pharmacol Ther. 2000. PMID: 11180020

• Pharmacokinetic interactions of drugs with St John's wort.

  Zhou S, Chan E, Pan SQ, Huang M, Lee EJ. Zhou S, et al. J Psychopharmacol. 2004 Jun;18(2):262-76. doi: 10.1177/0269881104042632. J Psychopharmacol. 2004. PMID: 15260917 Review.

• The emerging recognition of herb-drug interactions with a focus on St. John's wort (Hypericum perforatum).

  Markowitz JS, DeVane CL. Markowitz JS, et al. Psychopharmacol Bull. 2001 Winter;35(1):53-64. Psychopharmacol Bull. 2001. PMID: 12397870 Review.

Cited by

• Natural Product Use Among Veterans with Chronic Pain: A Qualitative Study of Attitudes and Communication with Healthcare Providers.

  Moore LC, Woodruff NA, Seal KH, Feinberg T, Purcell N. Moore LC, et al. J Gen Intern Med. 2024 Sep;39(12):2206-2214. doi: 10.1007/s11606-024-08746-2. Epub 2024 Apr 30. J Gen Intern Med. 2024. PMID: 38689119 Clinical Trial.

• Hypericum perforatum: Traditional uses, clinical trials, and drug interactions.

  Nobakht SZ, Akaberi M, Mohammadpour AH, Tafazoli Moghadam A, Emami SA. Nobakht SZ, et al. Iran J Basic Med Sci. 2022 Sep;25(9):1045-1058. doi: 10.22038/IJBMS.2022.65112.14338. Iran J Basic Med Sci. 2022. PMID: 36246064 Free PMC article. Review.

• Quantitative Prediction of Drug Interactions Caused by Cytochrome P450 2B6 Inhibition or Induction.

  Di Paolo V, Ferrari FM, Poggesi I, Quintieri L. Di Paolo V, et al. Clin Pharmacokinet. 2022 Sep;61(9):1297-1306. doi: 10.1007/s40262-022-01153-y. Epub 2022 Jul 20. Clin Pharmacokinet. 2022. PMID: 35857278

• St. John's wort (Hypericum perforatum) and depression: what happens to the neurotransmitter systems?

  Kholghi G, Arjmandi-Rad S, Zarrindast MR, Vaseghi S. Kholghi G, et al. Naunyn Schmiedebergs Arch Pharmacol. 2022 Jun;395(6):629-642. doi: 10.1007/s00210-022-02229-z. Epub 2022 Mar 16. Naunyn Schmiedebergs Arch Pharmacol. 2022. PMID: 35294606 Review.

• Physiologically Based Pharmacokinetic Modeling of Bupropion and Its Metabolites in a CYP2B6 Drug-Drug-Gene Interaction Network.

  Marok FZ, Fuhr LM, Hanke N, Selzer D, Lehr T. Marok FZ, et al. Pharmaceutics. 2021 Mar 4;13(3):331. doi: 10.3390/pharmaceutics13030331. Pharmaceutics. 2021. PMID: 33806634 Free PMC article.

Publication types

MeSH terms

Substances